# Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

> **NCT02499614** · PHASE2 · UNKNOWN · sponsor: **Fondazione Ricerca Traslazionale** · enrollment: 80 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02499614
- **Lead sponsor:** Fondazione Ricerca Traslazionale
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2018-06
- **Final completion:** 2018-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499614, "Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02499614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*